Skip to main content

India becomes Europe's top supplier of refined fuels

To keep you updated, we send Daily Newsletter to your mailbox. In case, you wish to Unsubscribe Click Here
The Economic Times

Daily Newsletter

Subscribe to ET Prime

Sun, Apr 30, 2023 | 05:00 PM IST

#NRI#EV Calculator#NewsLive!#WebStories
Top stories of the day
India becomes Europe's top supplier of refined fuel India becomes Europe's top supplier of refined fuel
The reliance of Europe on Indian crude oil products has surged. This increase can be linked with the ban on Russian o...
Through 'MannKiBaat', many movements gained momentum: PM Modi
India, Russia to explore accepting RuPay, Mir cards
Why no one can agree on updating India's EVMs
DGCA issues show cause notice to AI CEO
After a year, Jio-bp, Nayara sell fuel at market rates
Hindenburg v Adani, Fed action & 8 other factors that will steer Dalal Street
Uday Kotak clarifies his dollar statement
Why EPFO must extend deadline for higher EPS pension
5 reasons why product management is important in the software industry
NRI reckoner
US set to modernise H-1B visa registration after detecting fraud and abuse in computerised lottery system
The US Citizenship and Immigration Services (USCIS) plans to modernise the H-1B visa registration process to reduce fraud and abuse by some companies. The federal agency said only a small number of firms were responsible for entering the same candidates into the lottery repeatedly, artificially boosting their chances of winning a visa, with the abuse detected during FY23 and FY24 H-1B cap seasons.

Top Gainers

NSE
4 companies (largecap) appreciated more than 5%
PI Industries 10.40%
Indus Towers 7.01%
More from Gainers

Top Losers

NSE
1 company (largecap) price decreased more than -5%
Shriram Trans Fin -5.19%
More from Losers

Experience your trusted ET newspaper. Now in a brand new way.
The Economic Times print edition. Experience it now with your ET Prime membership.

Read Today's Print Edition
More From our Partners
ET Trailblazers: Poornima DeBolle on lessons as a cybersecurity leader and in steering a future for women in tech and entrepreneurship
At ET Trailblazers series featuring women leading the change in various fields, Menlo Security Co-founder Poornima DeBolle talks about her journey as a woman leader in cybersecurity, tech, and entrepreneurship. To enable more women in tech and entrepreneurship, the world needs more women role models and male allies, she says.
How India became home to the biggest, baddest cricket league How India became home to the biggest, baddest cricket league
In its 15th year, the tournament is raking in incredibly large amounts of money, recently adding a $6 billion broadca...
Maruti vulnerable as uncertainty continues
At 8.05% rate, this could be a better bet than bank FDs
Gas leak at Ludhiana factory kills 11
'Indian economy to grow at around 6.5%'
5,874 new Covid cases recorded in India
Airports on alert after exotic snake seizure
China's mfg contracts, signals recovery
Jaypee firm defaults on $508 mn loan
Shirdi temple to be open, Darshan, Aartis to continue
Google celebrates 'Harry Potter ' star's legacy
Time for malted milk drinks to reinvent themselves
Twitter saga: Blue is the colour, chaos is the name
More From our Partners
Efficiency can overcome the energy challenge – Why India needs to act now

The conclusions of this research could possibly set off alarm bells for business leaders and policymakers. However, the good news is that practical solutions to increase energy efficiency are now easily available, more accessible and affordable. Here is what Indian businesses need to know.

Follow Us on ET:
Facebook Twitter YouTube LinkedIn
About us|Advertise with us|Feedback|Sitemap|Code of Ethics
© 2023 Times Internet Limited.
To ensure delivery directly to your inbox, please add newsletter@economictimesnews.com to your address book today.
If you are having trouble viewing this newsletter, please click here
To unsubscribe or edit your subscriptions please click here

Comments

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side